UK Companies House feature
NEURENTIS PLC
Cash
£37K
+8,594.2% vs 2023
Net assets
£2M
-1.8% vs 2023
Employees
3
0% vs 2023
Profit before tax
-£37K
-38% vs 2023
Profile
- Company number
- 14461527
- Status
- Active
- Incorporation
- 2022-11-04
- Last accounts made up
- 2024-11-30
- Account category
- FULL
- Primary SIC
- 21100
- Hubs
- UK Healthcare
Net assets
2-year trend · vs UK Healthcare median
Accounts
2-year trend · latest 2024-11-30
| Metric | Trend | 2023-11-30 | 2024-11-30 |
|---|---|---|---|
| Turnover | — | — | |
| Operating profit | — | — | |
| Profit before tax | -£27,142 | -£37,469 | |
| Net profit | -£27,142 | -£37,469 | |
| Cash | £428 | £37,211 | |
| Total assets less current liabilities | — | — | |
| Net assets | £2,122,958 | £2,085,489 | |
| Equity | £2,122,958 | £2,085,489 | |
| Average employees | 3 | 3 | |
| Wages | — | — |
Values shown as filed in iXBRL accounts. — indicates the figure was not present in the extracted filing (either not filed under that concept or absent from the period). About these numbers
Audit & accounting basis
From AI-extracted PDF accounts
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- MHA
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The financial statements have been prepared on a going concern basis. The company currently has no ongoing trading commitments and meets its liabilities as they fall due from shareholder funding which the shareholders have confirmed they will continue to provide. The directors expect to raise substantial funds in due course to finance the growth and development of the company in line with their business plans, and will ensure that this will be sufficient to meet its commitments.”
Subsidiaries
- Neurentis (UK) Limited (Formerly Akesi Health Limited) · 100% held · UK · pharmaceutical
- Neurentis BV · 100% held · Belgium
Significant events
- “In 2024, Neurentis made a strategic breakthrough that significantly accelerated the development trajectory of our lead asset, the Quivara™™ patch for treatment-resistant depression (TRD). We entered into a confidential collaboration with a major U.S. pharmaceutical company, under which we plan to conduct a pivotal Phase 3 trial using our proprietary Quivara™™ brand.”
- “We signed an agreement with Netellis, a U.S.-based company at the forefront of artificial intelligence in drug discovery.”
- “We strengthened our leadership team during the reporting period with the addition of two Senior Vice Presidents, a New Product Development Manager and a seasoned Regulatory Advisor.”
Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers
People
4 active · 1 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| WHALLEY, Valerie Elizabeth | Secretary | 2022-11-04 | — | — |
| DIMITRIOU, Dimitri | Director | 2023-01-23 | Mar 1961 | British |
| MERY, Stephane Robert Georges, Dr | Director | 2023-01-23 | Apr 1965 | French |
| PREMI, Bijoy Kumar | Director | 2022-11-04 | Feb 1961 | British |
Show 1 resigned officer
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| DI MUZIO, Franco | Director | 2022-11-04 | 2023-01-23 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Dr Stephane Mery | Individual | Shares 25–50%, Voting 25–50% | 2023-02-02 | Active |
| Mr Dimitri Dimitriou | Individual | Shares 25–50%, Voting 25–50% | 2023-02-02 | Active |
| Franco Di Muzio | Individual | Shares 75–100%, Voting 75–100%, Appoints directors | 2022-11-04 | Ceased 2022-11-04 |
Filing timeline
Last 20 of 23 total filings
| Date | Type | Category | Description |
|---|---|---|---|
| 2026-03-02 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2025-09-30 | SH01 | capital | capital allotment shares |
| 2025-05-30 | AA | accounts | accounts with accounts type full |
| 2025-02-18 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2024-08-13 | AA | accounts | accounts with accounts type full |
| 2024-05-21 | RESOLUTIONS | resolution | resolution |
| 2024-05-21 | RESOLUTIONS | resolution | resolution |
| 2024-05-21 | RESOLUTIONS | resolution | resolution |
| 2024-05-17 | SH07 | capital | capital cancellation shares by plc |
| 2024-02-28 | CS01 | confirmation-statement | confirmation statement with updates |
| 2024-02-28 | AD01 | address | change registered office address company with date old address new address |
| 2023-06-10 | RESOLUTIONS | resolution | resolution |
| 2023-05-30 | SH01 | capital | capital allotment shares |
| 2023-05-30 | SH01 | capital | capital allotment shares |
| 2023-02-24 | PSC01 | persons-with-significant-control | notification of a person with significant control |
| 2023-02-22 | PSC01 | persons-with-significant-control | notification of a person with significant control |
| 2023-02-22 | PSC07 | persons-with-significant-control | cessation of a person with significant control |
| 2023-02-15 | SH01 | capital | capital allotment shares |
| 2023-02-14 | CS01 | confirmation-statement | confirmation statement with updates |
| 2023-01-24 | TM01 | officers | termination director company with name termination date |
Credit score
Altman Z″ — composite of working capital, retained earnings, EBIT, and leverage
Activity Score
Composite activity score · components 0–100 · reference 2026-05-10
31
COLD
/ 100
- Filings velocity 25
- Capital events 40
- Officer churn 0
- Headcount trajectory 50
- Accounts trajectory 48
- 3 filing(s) in last 12 months
- 2 capital event(s) in last 24 months
- Employees +0% YoY
- Net Assets -2% YoY